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Abstract: Background: There is increasing evidence that metabolic adverse effects associated with antiretroviral therapy 
may translate into an increased cardiovascular risk in HIV-1-infected patients. 
Objectives: To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-1-infected persons, 
and to investigate any association between them, stage of HIV-1 disease, and use of antiretroviral therapies. 
Methods: Multicentric, cross-sectional analysis of CVD risk factors of treated patients in the VACH cohort. The data col-
lected includes: demographic variables, cigarette smoking, diabetes mellitus, hypertension, dyslipidemia, body mass in-
dex, stage of HIV-1 infection, and antiretroviral therapy. 
Results: The analysis included 2358 patients. More than 18% of the study population was at an age of appreciable risk of 
CVD. 1.7% had previous CVD and 59.2% were smokers. Increased prevalence of elevated total cholesterol was observed 
among subjects receiving an NNRTI but no PI [odds ratio (OR), 3.34; 95% confidence interval (CI), 1.77–6.31], PI but no 
NNRTI (OR, 4.04; 95% CI, 2.12–7.71), or NNRTI + PI (OR, 17.77; 95% CI, 7.24–43.59) compared to patients treated 
only with nucleoside reverse transcriptase inhibitors (NRTI). Higher CD4 cell count, lower plasma HIV-1 RNA levels, 
clinical signs of lipodystrophy, longer exposure times to NNRTI and PI, and older age were all also associated with ele-
vated cholesterol levels. The use of lipid lowering agents was very low among our patients. 
Conclusion: Patients in the VACH cohort present multiple known risk factors for CVD, and a very low rate of lipid lower-
ing therapy use. NNRTI and/or PI-based antiretroviral therapies are associated with the worst lipid profile. This is more 
frequent in older subjects with greater CD4 counts and controlled HIV-1 replication. 
Keywords: HIV-1 infection, antiretroviral therapy, HIV-1 protease inhibitors, non nucleoside reverse transcriptase inhibitors, 
dyslipidemia, cardiovascular risk, coronary heart disease, VACH. 
INTRODUCTION 
  The widespread use of highly active antiretroviral ther-
apy (HAART) has converted HIV-1 infection into a chronic 
manageable illness that needs lifelong therapy. However, 
HAART is associated with metabolic side effects including 
hypercholesterolemia, hypertriglyceridemia, insulin resis-
tance and more rarely diabetes mellitus, and possibly arterial 
hypertension [1-4]. HAART-associated dyslipidemia is asso-
ciated with accelerated atherosclerosis [5-7] and signs of 
endothelial dysfunction [8]. How all these facts are   
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translated into clinical events of cardiovascular disease on a 
population level has been examined by a number of studies 
including cohort studies from the French Hospital Database 
[9], the HOPS Cohort [10], and the D:A:D multicohort study 
[11-13]. Overall, data from these cohorts suggest an in-
creased risk of coronary heart disease (CHD) for HIV-1-
infected patients on HAART [9-13]. 
  To assess the risk of treatment-associated cardiovascular 
risk factors, we performed a cross-sectional analysis of the 
HIV-1-infected patients included in the Spanish VACH Co-
hort. The objectives of the present analysis were to deter-
mine the proportion of patients with an increased risk profile 
for cardiovascular disease. Furthermore, we tried to identify 
factors associated with the increased risk profile. Addition- 
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ally, our research was focused on the management of dyslip-
idemia in our cohort. 
PATIENTS AND METHODS 
Design 
  The study is a multi-centre, cross-sectional study of the 
prevalence and management of dyslipidemia and other estab-
lished CHD/CVD risk factors in all HIV-1-infected subjects, 
aged 18 or above, treated with HAART, in routine clinical 
practice from the Spanish VACH cohort treatment centers. 
Characteristics of VACH Cohort have been described else-
where [14]. 
Study Population 
  Male or female subjects aged 18 years or above at the time 
of enrollment with a documented HIV-1 infection, which at-
tend VACH cohort outpatient HIV-1 treatment centers for 
routine, scheduled, clinical appointments, were eligible for this 
study. 
  In order to be eligible, subjects must have been on at 
least three antiretroviral drugs, at the time of the study visit. 
Antiretroviral (ARV) naïve subjects or ARV experienced, 
but currently untreated subjects or those currently treated 
with NRTI bi- or mono therapy were not eligible for this 
study. However, for the purpose of the study, we included 
patients treated with 3 NRTIs. Subjects who were hospital-
ized or have a frank cognitive impairment such as delirium 
or dementia on enrolment were not eligible either. Informed 
consent was obtained from the patients at study entry 
Data Collection 
  In the VACH Cohort, data are prospectively collected ac-
cording to standardized criteria, and are electronically stored 
in the Aplicación de Control Hospitalario (AC&H
TM), an ap-
plication specifically developed for the management of the 
cohort data. On enrolment, standardized data collection elec-
tronic forms were completed at the sites providing information 
from physical examination, patient interview and patient case 
notes, concerning family history of coronary heart disease, 
patients’ prior history of CVD and diabetes, cigarette smok-
ing, blood pressure, therapy for diabetes mellitus, lipid-
lowering and anti-hypertensive therapy, the presence of clini-
cal signs of lipodystrophy and fasting serum lipid levels. Fur-
ther, all cumulative data characterizing the patient’s underly-
ing HIV-1 infection since inclusion in any of the individual 
cohorts were collected, including information on demography, 
antiretroviral therapy, CD4 cell counts and HIV-1 viral loads. 
Dates of diagnosis of all AIDS-defining diseases are recorded, 
using the 1993 clinical definition of AIDS from the Centers 
for Disease Control and Prevention [15]. 
VARIABLES 
HIV-1 Laboratory Parameters 
  CD4 cell count was stratified in strata of 100 x 10
6 (cells/l) 
or assessed as a continuous variable (log2 transformed). Simi-
larly, HIV-1 RNA was stratified in strata of: < 500, 501–10 
000, 10 001–100 000, and > 100 000 copies/ml, and also as-
sessed as a continuous variable (log10 transformed). 
Antiretroviral Therapy 
  Four categories were predefined: (i) currently receiving 
only NRTI; (ii) currently receiving NNRTI and NRTI but 
not PI; (iii) currently receiving PI and NRTI but not NNRTI; 
or (iv) currently receiving PI, NNRTI and NRTI. Previous 
antiretroviral therapy exposure was modelled as cumulative 
time spent using each of the three drug classes. 
Cardiovascular Risk Factors and Managing Therapies 
  The grouping of the risk factors assessed was defined 
prior to the initiation of the analysis. CVD risk factors were 
assessed as dichotomous categorical variables, where the 
cut-off levels chosen were conservative estimates of ‘high 
risk’ based on levels used for risk scoring in the background 
population [16-19]. Patients were considered to be at high 
risk for CVD if they had dad a prior CVD event or had dia-
betes or more than two risk factors accounting for a CVD 10 
yr risk > 20%. Moderate-high risk was considered if patients 
had more than two risks factors accounting for a CVD 10 yr 
risk of 10-20%, whereas moderate risk was considered when 
patients more than 2 risk factors and a CVD 10 yr risk of less 
than 10%. Finally low risk patients were those who had no or 
only a risk factor. 
Cardiovascular Risk Calculation 
  Ten-year CHD risk estimates were calculated in accor-
dance with the equations of Wilson et al. [16] with use of 
sex-specific risk calculations based on age, total and HDL 
cholesterol levels, systolic and diastolic blood pressure, 
presence of diabetes (defined as a fasting glucose level of 
140 mg/dL), family history of CHD, personal history of 
CHD, and smoking status. The equation estimates the 10-
year risk for CHD events, including angina pectoris, myo-
cardial infarction, and death due to CHD. 
Statistical Analyses 
  We used frequencies, percentages and its 95% CI to de-
scribe categorical data, and median with interquartile range 
(IQR) for continuous variables. Univariable analysis was 
performed by means of the chi-squared and the Kruskal-
Wallis tests to compare categorical and continuous baseline 
demographic, clinical and laboratory characteristics. Asso-
ciation of CVD risk factors with antiretroviral therapy, 
demographic, clinical and laboratory parameters were tested 
in univariable logistic regression models. Multivariable lo-
gistic regression was then performed to identify parameters 
independently associated with the presence of CVD risk fac-
tors. The multivariable model included all parameters sig-
nificantly associated with the risk factor assessed, at a level 
of p<0.05 in the univariable model. 
  The analysis was performed using SAS version 9.1.3 
software (SAS Institute Inc, Cary, North Carolina, USA) and 
the level of significance was established at the 0.05 level 
(two-sided). 28    The Open AIDS Journal, 2008, Volume 2  Domingo et al. 
RESULTS 
Demographics 
  By April 2004, the central database contained informa-
tion on 2358 patients enrolled in VACH from fifteen partici-
pating Hospital cohorts. The patient characteristics are 
shown in Table 1. 
 
Antiretroviral Therapy 
  On enrolment, 9.9% were receiving a regimen containing 
NRTI only, 46.4% were receiving NNRTI-based therapy, 
41.9% PI-based therapy and 1.7% was on a regimen contain-
ing all three drug classes (Table 1). Sixty four percent of 
patients taking PI-based therapy had ritonavir-boosted PI on 
board while 0.02% were taking atazanavir. Overall, 72.6% of  
 
Table 1.  Demographic, Laboratory, Clinical and Antiretroviral Therapy Characteristics of the VACH Population at Baseline Ac-
cording to Current Usage of ART Drug Classes 
 
Current ART  
at Enrolment 
NRTI Only 
(n = 233) 
Combination with  
NNRTI (n = 1094) 
Combination with  
PI (n = 990) 
Combination with PI Plus  
NNRTI (n = 41) 
Total 
(n = 2358) 
p 
Age (years),  
median [IQR]
 & 
39.00 
[35.00,43.00] 
40.00  
[35.00,45.00] 
39.00 
[36.00,43.00] 
41.00 
[38.00,44.00] 
40.00  
[35.00,44.00]  0.0852 
Sex (% female) 
[95%CI] 
54 (23.2%)  
[17.9%,29.1%] 
243 (22.2%)  
[19.8%,24.8%] 
217 (21.9%)  
[19.4%,24.6%] 
8 (19.5%) 
[8.8%,34.9%] 
522 (22.1%)  
[20.5%,23.9%]  0.9450 
AIDS (%) 
[95%CI] 
57 (24.5%)  
[19.1%,30.5%] 
346 (31.6%)  
[28.9%,34.5%] 
367 (37.1%)  
[34.1%,40.2%]  18 (43.9%) [28.5%,60.3%]  788 (33.4%)  
[31.5%,35.4%]  0.0005 
HIV Acquisition
&  < 0.0001 
Injecting drug use  121 (52.2%)  
[45.5%,58.7%] 
443 (40.8%)  
[37.9%,43.8%] 
558 (56.7%)  
[53.5%,59.8%] 
18 (43.9%)  
[28.5%,60.3%] 
1140 (48.7%)  
[46.6%,50.7%]   
Homosexual  32 (13.8%)  
[9.6%,18.9%] 
245 (22.6%)  
[20.1%,25.2%] 
137 (13.9%)  
[11.8%,16.2%] 
8 (19.5%)  
[8.8%,34.9%] 
422 (18.0%)  
[16.5%,19.6%]   
Heterosexual  73 (31.5%)  
[25.5%,37.9%] 
344 (31.7%)  
[28.9%,34.5%] 
240 (24.4%)  
[21.7%,27.2%] 
10 (24.4%)  
[12.4%,40.3%] 
667 (28.5%)  
[26.6%,30.3%]   
Others  6 (2.6%)  
[1.0%,5.5%] 
54 (5.0%)  
[3.8%,6.4%] 
49 (5.0%) 
[3.7%,6.5%] 
5 (12.2%)  
[4.1%,26.2%] 
114 (4.9%)  
[4.0%,5.8%]   
CD4 cell count (x 106/l), 
median [IQR]
 & 
510.00  
[358.00,735.00] 
459.00  
[288.00,688.00] 
368.00  
[219.50,568.50] 
427.00  
[251.00,756.00] 
426.00  
[256.00,651.00]  < 0.0001 
HIV-1 RNA (log10), 
median [IQR]
 & 
1.69 
[1.69,1.70] 
1.69 
[1.69,1.99] 
1.70 
[1.69,2.44] 
1.70 
[1.69,2.30] 
1.69 
[1.69,2.17]  < 0.0001 
HIV-1 RNA copies/mL, 
median [IQR]
 & 
49.00 
[49.00,50.00] 
49.00 
[49.00,97.00] 
50.00 
[49.00,275.00] 
50.00 
[49.00,200.00] 
49.00 
[49.00,148.00]  0.0010 
HIV-1 RNA (log10),  
0median [IQR]
 & 
1.69 
[1.69,1.70] 
1.69 
[1.69,1.99] 
1.70 
[1.69,2.44] 
1.70 
[1.69,2.30] 
1.69 
[1.69,2.17]  < 0.0001 
ART exposure 
[median (IQR)] 
4.68 
[2.88,6.27] 
4.12 
[2.01,6.01] 
4.31 
[1.73,6.22] 
6.33 
[4.32,8.94] 
4.29 
[1.98,6.19]  < 0.0001 
HAART exposure 
[median (IQR)] 
4.59 
[2.71,5.96] 
4.00 
[1.93,5.61] 
4.04 
[1.64,5.80] 
6.11 
[4.10,6.95] 
4.10 
[1.90,5.79]  < 0.0001 
Exposure to PI (%) 
[95%CI] 
153 (65.7%)  
[59.2%,71.7%] 
527 (48.2%)  
[45.2%,51.2%] 
990 (100.0%)  
[99.7%,100.0%] 
41 (100.0%)  
[93.0%,100.0%] 
1711 (72.6%)  
[70.7%,74.4%]  < 0.0001 
Duration (years),  
median [IQR] 
4.27 
[0.00,5.95] 
0.00 
[0.00,5.55] 
3.80 
[1.21,5.86] 
6.11 
[2.53,6.98] 
3.26  
[0.00,5.80]  < 0.0001 
Exposure to NNRTIs (%)  
[95%CI] 
88 (37.8%)  
[31.5%,44.3%] 
1094 (100.0%)  
[99.7%,100.0%] 
357 (36.1%)  
[33.1%,39.1%] 
41 (100.0%)  
[93.0%,100.0%] 
1580 (67.0%)  
[65.1%,68.9%]  < 0.0001 
Duration (years), 
median [IQR] 
0.00 
[0.00,2.80] 
2.69  
[1.19,4.08] 
0.00 
[0.00,2.32] 
3.16 
[1.67,4.26] 
1.51 
[0.00,3.64]  < 0.0001 
Exposure to NRTI (%)  
[95%CI] 
233 (100.0%)  
[98.7%,100.0%] 
1092 (99.8%)  
[99.3%,100.0%] 
990 (100.0%)  
[99.7%,100.0%] 
40 (97.6%)  
[87.1%,99.9%] 
2355 (99.9%)  
[99.6%,100.0%]  0.0003 
Duration (years),  
median [IQR] 
4.68 
[2.88,6.27] 
4.10 
[2.01,6.01] 
4.31 
[1.72,6.22] 
6.33 
[4.32,8.94] 
4.28 
[1.98,6.19]  < 0.0001 
Descriptive statistics are n (%) [95%CI] for qualitative, and median [IQR] for qualitative variables. NRTI = nucleoside reverse transcriptase inhibitors, NNRTI = non-nucleoside 
reverse transcriptase inhibitors, PI = protease inhibitors, AIDS = acquired immunodeficiency syndrome, ART = antiretroviral therapy, HAART = highly active antiretroviral therapy. 
&Percentage of missingness <1%; null percentage for the rest of variables. Dyslipidemia and Cardiovascular Disease Risk Factor Management  The Open AIDS Journal, 2008, Volume 2    29 
the study population had at any time been exposed to PI with 
a median exposure time of 3.3 years (IQR, 0–5.8 years), 
67.0% had been exposed to NNRTI with a median exposure 
time of 1.5 years (IQR, 0–3.6 years) and 99.9% had been 
exposed to NRTI with a median exposure of 4.3 years (IQR, 
2.0–6.2 years) (Table 1). 
CVD Risk Factors and Association with Antiretroviral 
Therapy 
  CVD risk factors were prevalent in the study population 
(Table 2). More than 18% of the study population was in an 
age group constituting a CVD risk factor. Thirteen percent 
had a family history of coronary heart disease, and 1.7% had 
a previous history of CVD. Almost 60% of the study popula-
tion was current cigarette smokers. 
Serum Total Cholesterol 
  The association of antiretroviral therapy with lipid levels 
is shown in Table 2. Assessed from median cholesterol lev-
els (Table 2) and in univariable models (Table 3), patients 
currently using regimens containing all three drug classes 
were at increased risk of having a high total cholesterol when 
Table 2.  Cardiovascular Risk Factors in the VACH Cohort Population According to Current Usage of Antiretroviral Therapy 
(ART) Drug Classes 
 
  NRTI Only 
(n = 233) 
Combination with  
NNRTI (n = 1094) 
Combination with  
PI (n = 990) 
Combination with PI  
Plus NNRTI (n = 41) 
Total 
(n = 2358)  p 
Age > 45 years male,  
> 55 female,  
(%) [95%CI]
 & 
33 (14.2%)  
[10.0%,19.3%] 
244 (22.3%)  
[19.9%,24.9%] 
142 (14.4%)  
[12.2%,16.7%] 
7 (17.1%)  
[7.2%,32.1%] 
426 (18.1%)  
[16.5%,19.7%]  0.0001 
Body mass index,  
median [IQR] 
24.10 
[22.28,26.22] 
23.82 
[21.81,25.59] 
23.56  
[21.52,25.56] 
23.56 
[21.05,25.95] 
23.82 
[21.75,25.67]  0.0700 
Body mass index > 30 kg/m
2,  
(%) [95%CI] 
9 (3.9%)  
[1.8%,7.2%] 
29 (2.7%)  
[1.8%,3.8%] 
41 (4.1%)  
[3.0%,5.6%] 
3 (7.3%)  
[1.5%,19.9%] 
82 (3.5%)  
[2.8%,4.3%]  0.1428 
Current smoker,  
(%) [95%CI] 
146 (62.7%)  
[56.1%,68.9%] 
588 (53.7%)  
[50.7%,56.7%] 
641 (64.7%)  
[61.7%,67.7%] 
22 (53.7%)  
[37.4%,69.3%] 
1397 (59.2%)  
[57.2%,61.2%]  <0.0001 
Family story of CVD,  
(%) [95%CI] 
30 (12.9%)  
[8.9%,17.9%] 
157 (14.4%)  
[12.3%,16.6%] 
116 (11.7%)  
[9.8%,13.9%] 
3 (7.3%)  
[1.5%,19.9%] 
306 (13.0%)  
[11.6%,14.4%]  0.2227 
Previous CVD,  
(%) [95%CI] 
7 (3.0%)  
[1.2%,6.1%] 
17 (1.6%)  
[0.9%,2.5%] 
16 (1.6%)  
[0.9%,2.6%] 
0 (0.0%)  
[0.0%,7.0%] 
40 (1.7%)  
[1.2%,2.3%]  0.3520 
Hypertension,  
(%) [95%CI]
 & 
50 (21.5%)  
[16.4%,27.3%] 
272 (24.9%)  
[22.3%,27.5%] 
212 (21.4%)  
[18.9%,24.1%] 
5 (12.2%)  
[4.1%,26.2%] 
539 (22.9%)  
[21.2%,24.6%]  0.0886 
Diabetes mellitus,  
(%) [95%CI] 
21 (9.0%)  
[5.7%,13.4%] 
98 (9.0%)  
[7.3%,10.8%] 
52 (5.3%)  
[3.9%,6.8%] 
1 (2.4%)  
[0.1%,12.9%] 
172 (7.3%)  
[6.3%,8.4%]  0.0046 
Total cholesterol (mmol/l),  
median [IQR]
 
4.56 
[3.83,5.13] 
4.97 
[4.20,5.78] 
4.82 
[4.12,5.65] 
5.85 
[4.61,6.94] 
4.87 
[4.12,5.67]  <0.0001 
Total cholesterol > 6.2 mmol/l, 
(%) [95%CI] 
11 (4.7%)  
[2.4%,8.3%] 
172 (15.7%)  
[13.6%,18.0%] 
145 (14.6%)  
[12.5%,17.0%] 
18 (43.9%)  
[28.5%,60.3%] 
346 (14.7%)  
[13.3%,16.2%]  <0.0001 
HDL cholesterol (mmol/l),  
median [IQR] 
1.09 
[0.88,1.32] 
1.27 
[1.01,1.58] 
1.17 
[0.93,1.45] 
1.19 
[1.04,1.55] 
1.19 
[0.96,1.48]  <0.0001 
HDL cholesterol < 0.9 mmol/l,  
(%) [95%CI] 
60 (25.8%)  
[20.3%,31.9%] 
157 (14.4%)  
[12.3%,16.6%] 
216 (21.8%)  
[19.3%,24.5%] 
6 (14.6%)  
[5.6%,29.2%] 
439 (18.6%)  
[17.1%,20.2%]  <0.0001 
TC/HDL ratio  4.20 
[3.13,5.19] 
3.87 
[3.07,4.95] 
4.17 
[3.18,5.30] 
4.72 
[3.68,5.77] 
4.05 
[3.13,5.13]  <0.0001 
LDL cholesterol (mmol/l),  
median [IQR]
 & 
2.51 
[1.94,3.21] 
2.90 
[2.23,3.63] 
2.75 
[2.05,3.55] 
3.44 
[2.38,4.35] 
2.81 
[2.10,3.57]  <0.0001 
LDL cholesterol > 4.14 mmol/l,  
(%) [95%CI]
 & 
11 (4.8%)  
[2.4%,8.4%] 
142 (13.0%)  
[11.1%,15.2%] 
122 (12.4%)  
[10.4%,14.6%] 
12 (29.3%)  
[16.1%,45.5%] 
287 (12.2%)  
[10.9%,13.6%]  <0.0001 
Triglycerides (mmol/l),  
median [IQR] 
4.56 
[3.83,5.13] 
4.97 
[4.20,5.78] 
4.82 
[4.12,5.65] 
5.85 
[4.61,6.94] 
4.87 
[4.12,5.67]  <0.0001 
Triglycerides > 2.3 mmol/l,  
(%) [95%CI] 
58 (24.9%)  
[19.5%,31.0%] 
239 (21.8%)  
[19.4%,24.4%] 
294 (29.7%)  
[26.9%,32.7%] 
20 (48.8%)  
[32.9%,64.9%] 
611 (25.9%)  
[24.2%,27.7%]  <0.0001 
Lipodystrophy,  
(%) [95%CI] 
41 (17.6%)  
[12.9%,23.1%] 
200 (18.3%)  
[16.0%,20.7%] 
168 (17.0%)  
[14.7%,19.5%] 
11 (26.8%)  
[14.2%,42.9%] 
420 (17.8%)  
[16.3%,19.4%]  0.4027 
Descriptive statistics are n (%) [95%CI] for qualitative, and median [IQR] for qualitative variables. NRTI = nucleoside reverse transcriptase inhibitors, NNRTI = non-nucleoside 
reverse transcriptase inhibitors, PI = protease inhibitors, CVD = cardiovascular disease, LDL = low density lipoprotein, HDL = high density lipoprotein, TC = total cholesterol. 
&Percentage of missingness <1%; null percentage for the rest of variables. 30    The Open AIDS Journal, 2008, Volume 2  Domingo et al. 
compared with patients using regimen containing only 
NRTI. This pattern remained unchanged after controlling for 
other risk factors (Table 4). In a univariable logistic model 
for cumulative antiretroviral therapy exposure time, the OR 
increment of risk for elevated total cholesterol was 9% 
(p=0.005), 2% (p=0.251) and 2% (p=0.314) per year of ex-
posure to NRTI, NNRTI and PI, respectively (Table 3). The 
level of immunodeficiency and plasma HIV-1 RNA were 
independently associated with elevated total cholesterol after 
adjustment for other factors (Fig. 1). Overall, the adjusted 
risk of having elevated total cholesterol increased by 31% 
per twofold increase in CD4 cell count [OR, 1.31; IC95%: 
1.16-1.47 per log2CD4, P < 0.001] (Fig. 1). In all antiretrovi-
ral therapy groups, higher HIV-1 viral load was associated 
with a decreased risk of elevated total cholesterol (Fig. 1); 
overall the adjusted OR was 0.77 (95%CI: 0.68-0.88), P < 
0.001, per 1 log10 increase in HIV-1 RNA. 
Serum Triglycerides 
  In a univariable logistic model for cumulative antiretrovi-
ral drug exposure time, the OR for elevated triglycerides was 
1.05 (95%CI, 1.02-1.09), 1.02 (95%CI, 0.97-1.07) and 1.06 
(95%CI, 1.02-1.09) per year of exposure to NRTI, NNRTI 
and PI, respectively, associations essentially unchanged in 
the multivariable model (Tables 3 and 4). Overall, the ad-
Table 3.  Association of Current Antiretroviral Therapy (ART) with BMI, Hypertension, Diabetes, Dyslipidaemia, and Lipodys-
trophy at Baseline. Results from Logistic Regression Models, Univariable and Adjusted for Other Factors 
 
Only NRTI  NNRTI  PI  NNRTI+PI 
 
Ref.   OR  95%CI  p  OR  95%CI  p  OR  95%CI  p 
BMI>30kg/m
2 
Univariant  [1]  0.69 0.31 1.55 0.373 1.13 0.52 2.45  0.761  2.08 0.53 8.20 0.294 
Multivariable  [1]  0.63 0.28 1.42 0.266 1.13 0.52 2.46  0.756  1.91 0.48 7.57 0.359 
Diabetes 
Univariant  [1]  1.12 0.66 1.90 0.672 0.59 0.34 1.04  0.069  0.28 0.04 2.15 0.221 
Multivariable  [1]  0.98 0.57 1.68 0.933 0.60 0.34 1.06  0.079  0.25 0.03 1.97 0.189 
HDL <=0.9mmol/l 
Univariant  [1]  0.48 0.34 0.68 0.000 0.79 0.56 1.11  0.174  0.49 0.19 1.22 0.124 
Multivariable  [1]  0.45 0.32 0.65 0.000 0.67 0.47 0.95  0.025  0.38 0.15 0.98 0.045 
Hypolipemiant drugs 
Univariant  [1]  1.26 0.52 3.02 0.610 0.76 0.30 1.92  0.566  NE NE NE  0.984 
Multivariable  [1]  1.36 0.56 3.31 0.500 0.88 0.34 2.27  0.796  NE NE NE  0.983 
Hypertension 
Univariant  [1]  1.35 0.94 1.94 0.105 1.10 0.76 1.59  0.599  0.57 0.21 1.53 0.265 
Multivariable  [1]  1.28 0.88 1.88 0.198 1.26 0.86 1.86  0.238  0.57 0.21 1.59 0.283 
Lipodystrophy 
Univariant  [1]  0.99 0.68 1.44 0.970 0.92 0.63 1.35  0.685  1.59 0.74 3.44 0.237 
Multivariable  [1]  0.63 0.28 1.42 0.266 1.13 0.52 2.46  0.756  1.91 0.48 7.57 0.359 
Cardiovascular Risk (moderate-high) 
Univariant  [1]  0.93 0.67 1.30 0.671 0.84 0.60 1.18  0.315  0.71 0.31 1.62 0.410 
Multivariable  [1]  0.63 0.28 1.42 0.266 1.13 0.52 2.46  0.756  1.91 0.48 7.57 0.359 
Total Cholesterol >= 6.2 mmol/l 
Univariant  [1]  3.54 1.89 6.64 0.000 3.21 1.70 6.04  0.000  14.80 6.23 35.14 0.000 
Multivariable  [1]  3.34 1.77 6.31 0.000 4.04 2.12 7.71  0.000  17.77 7.24 43.59 0.000 
TG >= 2.3 mmol/l 
Univariant  [1]  0.85 0.60 1.20 0.356 1.31 0.93 1.83  0.122  2.98 1.50 5.92 0.002 
Multivariable [1]  0.81 0.57 1.15 0.241 1.40 0.99 1.99  0.059  2.80 1.39 5.65 0.004 
The final multivariable model included variables that were significantly (P<0.05) associated with the cardiovascular risk factor in question. The following variables were tested age, 
gender, smoking, family history of coronary heart disease, previous cardiovascular disease, body mass index, transmission mode, CD4 cell count, HIV RNA, previous AIDS. PI, 
protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; CI, confidence interval; HDL, high den-
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justed risk of elevated triglycerides decreased with increas-
ing HIV-1 RNA [OR (95%CI), 0.86(0.78 to 0.95) per 1 log10 
increase; P = 0.002], and there was also a significant associa-
tion with CD4 cell count [OR, 1.20 (IC95%: 1.10 to 1.31) 
per log2 CD4 twofold increase; P < 0.001]. 
Serum HDL-Cholesterol 
  None of the current regimens were associated with an 
increased risk of low HDL-cholesterol (Tables 2-4) in the 
multivariate logistic model. The associations of CD4 cell 
count and HIV-1 viral load were similar for the absolute 
value of HDL-cholesterol and for total cholesterol. 
Hypertension 
  More than 20% of the study population had hypertension. 
In a univariable logistic model, regimens containing NNRTI, 
PI or both drug classes were associated with a non statisti-
cally different risk of being hypertensive (Tables 3 and 4) 
which was explained by a strong correlation of hypertension 
with other factors (age, sex and BMI). 
Diabetes 
  The overall prevalence of diabetes was 7.3%. In a uni-
variable model, all regimens were associated with a differen- 
 
Table 4.  Risk for BMI, Hypertension, Diabetes, Dyslipidaemia, and Lipodystrophy at Baseline. Per Year of ART Exposure for 
HAART, NNRTI, NRTI, and PI. Results from Logistic Regression Models, Univariable and Adjusted for Other Factors 
 
Risk Per Year of HAA  
Exposure 
Risk Per Year of NRTI  
Exposure 
Risk Per Year of NNRTI  
Exposure 
Risk Per Year of PI  
Exposure   
OR 95%CI  p OR  95%CI  p OR  95%CI  p OR  95%CI p 
BMI>30kg/m
2 
Univariant 0.95  0.86  1.05  0.329  0.93 0.85 1.01  0.091  0.96 0.85 1.09  0.546  0.98  0.90  1.06  0.570 
Multivariable 0.95  0.87  1.05  0.358  0.93 0.86 1.01  0.104  0.95 0.84 1.08  0.443  0.98  0.90  1.06  0.626 
Diabetes 
Univariant 1.09  1.01  1.17  0.018  1.06 1.00 1.12  0.036  1.11 1.02 1.20  0.011  1.03  0.97  1.09  0.295 
Multivariable 1.09  1.01  1.17  0.020  1.08 1.02 1.14  0.011  1.10 1.01 1.19  0.031  1.04  0.98  1.10  0.243 
HDL <=0.9 mmol/l 
Univariant 0.99  0.94  1.03  0.590  1.00 0.96 1.03  0.834  0.93 0.88 0.99  0.018  1.01  0.97  1.05  0.627 
Multivariable 1.01  0.96  1.06  0.638  1.01 0.97 1.05  0.633  0.96 0.91 1.02  0.221  1.02  0.98  1.06  0.391 
Hypolipemiant drugs 
Univariant 1.18  1.06  1.32  0.003  1.11 1.02 1.20  0.014  1.22 1.08 1.39  0.002  1.08  0.99  1.18  0.097 
Multivariable 1.16  1.03  1.30  0.014  1.10 1.01 1.20  0.032  1.19 1.05 1.36  0.007  1.06  0.97  1.16  0.209 
Hypertension 
Univariant 1.06  1.02  1.11  0.004  1.05 1.02 1.09  0.003  1.07 1.02 1.13  0.007  1.03  1.00  1.07  0.070 
Multivariable 1.06  1.01  1.11  0.017  1.06 1.02 1.10  0.002  1.06 1.00 1.11  0.051  1.03  1.00  1.07  0.070 
Lipodystrophy 
Univariant 1.32  1.25  1.39  0.000  1.19 1.15 1.24  0.000  1.16 1.10 1.23  0.000  1.21  1.16  1.26  0.000 
Multivariable 1.30  1.23  1.37  0.000  1.18 1.14 1.23  0.000  1.13 1.07 1.20  0.000  1.19  1.14  1.24  0.000 
Risk (moderate-high) 
Univariant 1.07  1.03  1.12  0.001  1.05 1.02 1.09  0.004  1.07 1.02 1.12  0.008  1.04  1.00  1.07  0.044 
Multivariable 1.07  1.02  1.12  0.004  1.07 1.03 1.11  0.001  1.05 0.99 1.11  0.079  1.04  1.00  1.08  0.041 
Total Cholesterol >= 6.2 mmol/l 
Univariant 1.04  0.99  1.10  0.093  1.02 0.98 1.06  0.314  1.09 1.03 1.16  0.005  1.02  0.98  1.07  0.251 
Multivariable 1.03  0.98  1.09  0.268  1.03 0.98 1.08  0.242  1.04 0.98 1.11  0.190  1.03  0.98  1.07  0.221 
TG >= 2.3 mmol/l 
Univariant 1.06  1.02  1.11  0.003  1.05 1.02 1.09  0.001  1.02 0.97 1.07  0.370  1.06  1.02  1.09  0.001 
Multivariable 1.04  1.00  1.09  0.068  1.04 1.01 1.08  0.016  0.99 0.94 1.04  0.770  1.05  1.01  1.08  0.012 
The final multivariable model included variables that were significantly (P<0.05) associated with the cardiovascular risk factor in question. The following variables were tested age, 
gender, smoking, family history of coronary heart disease, previous cardiovascular disease, body mass index, transmission mode, CD4 cell count, HIV RNA, previous AIDS. PI, 
protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; CI, confidence interval; HDL, high den-
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Table 5.  Cardiovascular Risk Factors in the VACH Cohort Population According to the Presence of Fat Redistribution 
 
  Without LD (n=1938)  With LD (n=420)  Total  (n=2358)  p 
Age (years), median [IQR]  39.00 
[35.00,44.00] 
41.00 
[37.00,46.00] 
40.00 
[35.00,44.00]  <0.0001 
Age > 45 years male, > 55 female, n (%) [95%CI]  331 (17.1%)  
[15.4%,18.8%] 
95 (22.6%)  
[18.7%,26.9%] 
426 (18.1%)  
[16.5%,19.7%]  0.0076 
Body mass index, median [IQR]  23.80 
[21.72,25.65] 
23.83 
[21.84,25.85] 
23.82 
[21.75,25.67]  0.5305 
Body mass index > 30 kg/m2 median, n (%) [95%CI]  74 (3.8%)  
[3.0%,4.8%] 
8 (1.9%)  
[0.8%,3.7%] 
82 (3.5%)  
[2.8%,4.3%]  0.0523 
Current smoker, n (%) [95%CI]  1141 (58.9%)  
[56.6%,61.1%] 
256 (61.0%)  
[56.1%,65.6%] 
1397 (59.2%)  
[57.2%,61.2%]  0.4322 
Sex (female), n (%) [95%CI]  439 (22.7%)  
[20.8%,24.6%] 
83 (19.8%)  
[16.1%,23.9%] 
522 (22.1%)  
[20.5%,23.9%]  0.1959 
Clinical AIDS, n (%) [95%CI]  630 (32.5%)  
[30.4%,34.6%] 
158 (37.6%)  
[33.0%,42.4%] 
788 (33.4%)  
[31.5%,35.4%]  0.0441 
Clinical or Immunologic AIDS, n (%) [95%CI]  1100 (56.8%)  
[54.5%,59.0%] 
268 (63.8%)  
[59.0%,68.4%] 
1368 (58.0%)  
[56.0%,60.0%]  0.0080 
CD4 cell count (x 106/l), median [IQR)]  414.00  
[249.50,628.50] 
480.00  
[310.00,713.00] 
426.00  
[256.00,651.00]  <0.0001 
Nadir CD4 cell count (x 106/l), median [IQR)]  141.00  
[49.00,252.00] 
130.00  
[47.00,240.00] 
140.00  
[48.00,250.00]  0.3251 
Time from HIV diagnosis (years), median [IQR)]  7.21 
[4.02,12.47] 
9.08 
[6.26,13.98] 
7.46 
[4.42,12.75]  <0.0001 
HIV-1 RNA (log10), median [IQR)]  1.70 
[1.69,2.24] 
1.69 
[1.69,1.85] 
1.69 
[1.69,2.17]  0.0011 
ART exposure (years), median [IQR)]  4.01 
[1.72,5.95] 
5.51 
[3.75,6.85] 
4.29 
[1.98,6.19]  <0.0001 
HAART exposure (years), median [IQR)]  3.80 
[1.65,5.52] 
5.29 
[3.70,6.56] 
4.10 
[1.90,5.79]  <0.0001 
Exposure to PI, n (%) [95%CI]  1363 (70.3%)  
[68.2%,72.4%] 
348 (82.9%)  
[78.9%,86.3%] 
1711 (72.6%)  
[70.7%,74.4%]  <0.0001 
Duration (years), median [IQR)]  2.42 
[0.00,5.53] 
5.25 
[1.98,6.64] 
3.26 
[0.00,5.80]  <0.0001 
Exposure to NNRTIs, n (%) [95%CI]  1283 (66.2%)  
[64.0%,68.3%] 
297 (70.7%)  
[66.1%,75.0%] 
1580 (67.0%) 
[65.1%,68.9%]  0.0746 
Duration (years), median [IQR)]  1.33 
[0.00,3.45] 
2.49 
[0.00,4.17] 
1.51 
[0.00,3.64]  <0.0001 
Exposure to NRTIs, n (%) [95%CI]  1935 (99.8%)  
[99.5%,100.0%] 
420 (100.0%)  
[99.3%,100.0%] 
2355 (99.9%) 
[99.6%,100.0%]  0.4198 
Duration (years), median [IQR)]  4.00 
[1.72,5.94] 
5.51 
[3.73,6.85] 
4.28 
[1.98,6.19]  <0.0001 
Family story of CVD, n (%) [95%CI]  236 (12.2%)  
[10.8%,13.7%] 
70 (16.7%)  
[13.2%,20.6%] 
306 (13.0%)  
[11.6%,14.4%]  0.0131 
Previous CVD, n (%) [95%CI]  33 (1.7%)  
[1.2%,2.4%] 
7 (1.7%)  
[0.7%,3.4%] 
40 (1.7%)  
[1.2%,2.3%]  0.9586 
Hypertension, n (%) [95%CI]  412 (21.3%) [ 
19.5%,23.2%] 
127 (30.2%)  
[25.9%,34.9%] 
539 (22.9%)  
[21.2%,24.6%]  <0.0001 
Diabetes mellitus [% (95% CI) 
121 (6.2%)  
[5.2%,7.4%] 
51 (12.1%)  
[9.2%,15.7%] 
172 (7.3%)  
[6.3%,8.4%]  <0.0001 
Total cholesterol (mmol/l), median [IQR)]
  4.87 
[4.14,5.67] 
4.84 
[3.96,5.67] 
4.87 
[4.12,5.67]  0.2802 
Total cholesterol > 6.2 mmol/l, n (%) [95%CI] 
280 (14.4%)  
[12.9%,16.1%] 
66 (15.7%)  
[12.4%,19.6%] 
346 (14.7%)  
[13.3%,16.2%]  0.5061 Dyslipidemia and Cardiovascular Disease Risk Factor Management  The Open AIDS Journal, 2008, Volume 2    33 
 
tial risk of diabetes (Tables 3 and 4). The adjusted multivari-
ate increment of risk per year of exposure was 8% for NRTI 
(p=0.011), 10% for NNRTI (p=0.031) and 4% for PI (0.243) 
(Table 4). 
Body Composition 
  In all regimen groups there were few obese patients (Ta-
ble 2). Antiretroviral therapy was highly associated with the 
presence of clinical lipodystrophy, with the highest risk 
among patients receiving a regimen containing all three drug 
classes (Tables 3 and 4). When assessed as an explanatory 
variable, lipodystrophy was associated with the presence of 
several of the CVD risk factors discussed above (Table 5). In 
a multivariable model including the total study population, 
and adjusting for co-variables as listed in Table 5, the ad-
justed OR for the association of lipodystrophy with elevated 
total cholesterol was 0.90 (0.65-1.23; P = 0.494), elevated 
triglycerides 1.36 (1.06-1.75; P = 0.017) and decreased HDL 
1.19 (0.90.1.58; P = 0.214). The presence of lipodystrophy 
was associated with an increased risk of hypertension and 
diabetes OR, 1.47 (95%CI, 1.14–1.90; P = 0.003) and 1.71 
(95%CI, 1.17–2.49, P = 0.005), respectively. 
Cardiovascular Risk Assessment 
  Ten-year CHD risk estimates for HIV-1-infected subjects 
treated with HAART in the VACH cohort are shown in Ta-
ble 6. There was no clustering of CHD risk for any treatment 
group. The 10-year CHD of moderate-high or high risk esti-
mate was significantly increased among HIV-1-infected pa-
tients with fat redistribution, compared with that for those 
with no redistribution: 48.5% versus 37.9%, (P < 0.001) 
(Table 5). Ten-year CHD risk estimates were studied by cur-
rent HAART regimen (Table 6) and by cumulated ART ex-
posure (Table 4). Predictors of a moderate-high CVD risk 
estimate obtained from the multivariate logistic model were: 
OR (95%CI; P value): 0.63 (0.28-1.42; P = 0.266), 1.13 
(Table 5) contd….. 
  Without LD (n=1938)  With LD (n=420)  Total  (n=2358)  p 
HDL cholesterol (mmol/l), median [IQR)]  1.22 
[0.98,1.50] 
1.11 
[0.91,1.40] 
1.19 
[0.96,1.48]  0.0002 
HDL cholesterol < 0.9 mmol/l, n (%) [95%CI]  347 (17.9%) [ 
16.2%,19.7%] 
92 (21.9%)  
 [18.0%,26.2%] 
439 (18.6%)  
[17.1%,20.2%]  0.0562 
TC/HDL ratio  4.00 
[3.11,5.07] 
4.24 
 [3.23,5.37] 
4.05 
[3.13,5.13]  0.0184 
LDL cholesterol (mmol/l), median [IQR)]
 &  2.82 
[2.12,3.57] 
2.77 
 [1.99,3.55] 
2.81 
[2.10,3.57]  0.3614 
LDL cholesterol > 4.14 mmol/l, n (%) [95%CI]
 &  235 (12.2%)  
[10.7%,13.7%] 
52 (12.4%)  
[9.4%,16.0%] 
287 (12.2%)  
[10.9%,13.6%]  0.8812 
Triglycerides (mmol/l), median [IQR)]  1.53 
[1.06,2.27] 
1.70 
[1.18,2.82] 
1.55 
[1.08,2.35]  <0.0001 
Triglycerides > 2.3 mmol/l, n (%) [95%CI]  469 (24.2%)  
[22.3%,26.2%] 
142 (33.8%)  
[29.3%,38.6%] 
611 (25.9%)  
[24.2%,27.7%]  <0.0001 
10-year cardiovascular risk estimate, n (%) [95%CI]  <0.0001 
Low  193 (10.0%)  
[8.7%,11.4%] 
68 (16.2%)  
[12.8%,20.1%] 
261 (11.1%)  
[9.8%,12.4%]   
Moderate  1009 (52.1%)  
[49.8%,54.3%] 
148 (35.2%)  
[30.7%,40.0%] 
1157 (49.1%)  
[47.0%,51.1%]   
Moderate-high  495 (25.5%)  
[23.6%,27.5%] 
145 (34.5%)  
[30.0%,39.3%] 
640 (27.1%)  
[25.4%,29.0%]   
High  241 (12.4%)  
[11.0%,14.0%] 
59 (14.0%)  
[10.9%,17.7%] 
300 (12.7%)  
[11.4%,14.1%]   
Risk factor number, n (%) [95%CI]  <0.0001 
0  542 (28.0%)  
[26.0%,30.0%] 
71 (16.9%) 
[13.4%,20.8%] 
613 (26.0%)  
[24.2%,27.8%]   
1  668 (34.5%)  
[32.4%,36.6%] 
131 (31.2%)  
[26.8%,35.9%] 
799 (33.9%)  
[32.0%,35.8%]   
 2  728 (37.6%)  
[35.4%,39.8%] 
218 (51.9%)  
[47.0%,56.8%] 
946 (40.1%)  
[38.1%,42.1%]   
Descriptive statistics are n (%) [95%CI] for qualitative, and median [IQR] for qualitative variables. LD = lipodystrophy, AIDS = acquired immunodeficiency syndrome, ART = 
antiretroviral therapy, HAART = highly active antiretroviral therapy, CVD = cardiovascular disease, PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; 
NRTI = nucleoside reverse transcriptase inhibitor; OR = odds ratio; CI = confidence interval; HDL= high density lipoprotein; TC = total cholesterol. 
&Percentage of missingness <1%; null percentage for the rest of variables. 34    The Open AIDS Journal, 2008, Volume 2  Domingo et al. 
(0.52-2.46; P = 0.756), and 1.91 (0.48-7.57; P =0.359) for 
NRTI, PI, NNRTI+PI current ART regimens, respectively. 
Lipid-Lowering Therapy (LLT) 
  The proportion of patients who fulfilled criteria for being 
treated with LLT were 11.3%, 18.5%, 17.9%, and 26.8%, 
respectively for patients treated with NRTI only or with 
NNRTI, PI or NNRTI and PI, respectively (P = 0.0243). 
However, only between a fourth and a fifth of those patients 
were currently receiving LLT. 
DISCUSSION 
  In the VACH population we have observed a high preva-
lence of multiple risk factors for CVD. VACH has the 
strength of having included more than 2000 treated patients 
with details concerning CVD risk factors, with an almost 
insignificant proportion of missing data. Similar to other 
studies [13], we found that regimens containing drugs from 
both the PI and NNRTI classes were associated with the 
highest prevalence of dyslipidemia. Furthermore, we also 
observed that hypercholesterolemia was associated with a 
higher CD4 cell count, a lower HIV-1 plasma viral load, the 
presence of clinical signs of lipodystrophy and older age. 
These findings, and those of others [13, 20], suggest that 
immune reconstitution phenomena may play some role in the 
development of antiretroviral-associated dyslipidemia. 
  However, our findings have inherent limitations. Firstly, 
our findings are not applicable to other populations since the 
diversity of the study population, including women, minori-
ties and means of acquiring HIV-1 infection, implies that the 
study may not be representative of the HIV-1-infected popu-
lation in other industrialized countries. Furthermore, the 
Mediterranean basin is an area of low incidence in terms of 
coronary heart disease and its risk factors, which may make 
comparisons with similar studies difficult [21, 22]. However, 
our study suggests that even in such an environment, HIV-1-
infected patients on HAART develop comparable metabolic 
disturbances to other geographically-based cohorts [23-25]. 
Since information concerning certain other potential risk 
factors for CVD, such as diet, physical activity and genetic 
Table 6.  Cardiovascular Risk Assessment and Need for Lipid-Lowering Therapy (LLT) in the VACH Cohort Population Accord-
ing to Current Usage of Antiretroviral Therapy (ART) Drug Classes 
 
  NRTI Only  
(n = 233) 
Combination with  
NNRTI (n = 1094) 
Combination with  
PI (n = 990) 
Combination with  
PI plus NNRTI (n = 41) 
Total  
(n = 2358)  p 
Risk factor number, n (%) [95%CI]  0.0001 
0   42 (18.0%)  
[13.3%,23.6%] 
326 (29.8%)  
[27.1%,32.6%] 
228 (23.0%)  
[20.4%,25.8%] 
17 (41.5%)  
[26.3%,57.9%] 
613 (26.0%)  
[24.2%,27.8%]   
1   78 (33.5%)  
[27.4%,39.9%] 
363 (33.2%)  
[30.4%,36.1%] 
345 (34.8%)  
[31.9%,37.9%] 
13 (31.7%)  
[18.1%,48.1%] 
799 (33.9%)  
[32.0%,35.8%]   
 2   113 (48.5%)  
[41.9%,55.1%] 
405 (37.0%)  
[34.2%,40.0%] 
417 (42.1%)  
[39.0%,45.3%] 
11 (26.8%)  
[14.2%,42.9%] 
946 (40.1%)  
[38.1%,42.1%]   
10-yr Cardiovascular risk estimate, n (%) [95%CI] 
Low  107 (45.9%)  
[39.4%,52.6%] 
548 (50.1%)  
[47.1%,53.1%] 
475 (48.0%)  
[44.8%,51.1%] 
27 (65.9%)  
[49.4%,79.9%] 
1157 (49.1%)  
[47.0%,51.1%]  0.0184 
Moderate  65 (27.9%)  
[22.2%,34.1%] 
280 (25.6%)  
[23.0%,28.3%] 
289 (29.2%)  
[26.4%,32.1%] 
6 (14.6%)  
[5.6%,29.2%] 
640 (27.1%)  
[25.4%,29.0%]   
Moderate-high  34 (14.6%)  
[10.3%,19.8%] 
124 (11.3%)  
[9.5%,13.4%] 
138 (13.9%)  
[11.8%,16.3%] 
4 (9.8%)  
[2.7%,23.1%] 
300 (12.7%)  
[11.4%,14.1%]   
High  27 (11.6%)  
[7.8%,16.4%] 
142 (13.0%)  
[11.0%,15.1%] 
88 (8.9%)  
[7.2%,10.8%] 
4 (9.8%)  
[2.7%,23.1%] 
261 (11.1%)  
[9.8%,12.4%]   
Lipid-lowering therapy, n (%) [95%CI]
 & 
Needed  26 (11.3%)  
[7.5%,16.1%] 
201 (18.5%)  
[16.2%,20.9%] 
177 (17.9%)  
[15.6%,20.5%] 
11 (26.8%)  
[14.2%,42.9%] 
415 (17.7%)  
[16.2%,19.3%]  0.0243 
Current use  6 (2.6%)  
[1.0%,5.5%] 
36 (3.3%) 
[2.3%,4.5%] 
21 (2.1%)  
[1.3%,3.2%] 
0 (0.0%) 
[0.0%,7.0%] 
63 (2.7%) 
[2.1%,3.4%]  0.2725 
Type of therapy, n (%) [95%CI]  0.3161 
None  227 (97.4%)  
[94.5%,99.0%] 
1058 (96.7%)  
[95.5%,97.7%] 
969 (97.9%)  
[96.8%,98.7%] 
41 (100.0%)  
[93.0%,100.0%] 
2295 (97.3%)  
[96.6%,97.9%]   
Fibrates  3 (1.3%)  
[0.3%,3.7%] 
12 (1.1%) 
[0.6%,1.9%] 
12 (1.2%)  
[0.6%,2.1%] 
0 (0.0%) 
[0.0%,7.0%] 
27 (1.1%)  
[0.8%,1.7%]   
Statines  3 (1.3%)  
[0.3%,3.7%] 
24 (2.2%) 
[1.4%,3.2%] 
9 (0.9%)  
[0.4%,1.7%] 
0 (0.0%) 
[0.0%,7.0%] 
36 (1.5%)  
[1.1%,2.1%]   
Descriptive statistics are n (%) [95%CI] for qualitative, and median [IQR] for qualitative variables. 
&Percentage of missingness <1%; null percentage for the rest of variables. Dyslipidemia and Cardiovascular Disease Risk Factor Management  The Open AIDS Journal, 2008, Volume 2    35 
factors, was not collected in our study, this may restrict the 
validity of our findings only to populations similar to ours. 
  Other limitations are related to the observational design 
of the study. Firstly, the results presented are only associa-
tions from which no conclusions regarding causality can or 
should be drawn. Secondly, due to the observational design 
of the study, many measurements (blood pressure, lipid lev-
els) are expected not to be always conducted in a uniform 
manner. However, international and national standardization 
of serum lipid measurements have been accomplished 
throughout the guidelines of the NCEP ATP II and the Span-
ish Society of Hypertension [19, 26]. On the other hand, the 
relatively low proportion of missing data should be noted 
(Table 1), which implies that the prevalence of the individual 
risk factors is precise. 
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Fig. (1). Prevalence of elevated total cholesterol (> 6.2 mmol/l) according to current antiretroviral therapy (ART), CD4 cell count (a) and 
HIV RNA (b) at baseline. The four ART categories are: NRTI (currently receiving only NRTI), NNRTI (currently receiving NNRTI and 
NRTI but not PI), PI (currently receiving PI and NRTI but not NNRTI), and PI/NNRTI (currently receiving PI, NNRTI and NRTI). 36    The Open AIDS Journal, 2008, Volume 2  Domingo et al. 
  Dyslipidemia was most strongly correlated with antiret-
roviral regimens currently being used, and less with a history 
of previous exposure to the different drug classes. This is 
consistent with previous reports, in which the PI-associated 
dyslipidemia occurred shortly after beginning therapy [27, 
28] and it is also consistent with studies showing that a 
switch from PI to NNRTI-based or NRTI-only regimens is 
associated with attenuation or resolution of dyslipidemia [29, 
30]. The average increases in lipid levels [2, 13, 31, 32], 
comparing levels during PI therapy with either pre-therapy 
levels or levels in PI-naïve HIV-1-infected patients, were 
28% for total cholesterol and 96% for triglycerides. We ob-
served no difference in risk of low HDL-cholesterol among 
patients treated with PI, NRTI or NNRTIs, data reported by 
others as well [13, 26]. Duration of PI therapy did not influ-
ence the level of HDL cholesterol [32], whereas duration of 
NRTI was associated with a higher risk of low HDL-
cholesterol. 
  The association between NNRTI-containing regimens 
and dyslipidemia has rarely been reported [13], although, in 
phase I studies of efavirenz in HIV-1-uninfected subjects 
revealed increases in total cholesterol levels of 10–20% in 
some subjects [3], whereas cohort and trial data suggest that 
18-20% of NNRTI-treated patients develop dyslipidemia 
[23-25, 34]. Although a different lipid profile between the 
two NNRTIs used has been frequently claimed [30], no dif-
ferences were reported in HIV-1-infected individuals [35]. In 
concordance with our results, an increase in HDL-cholesterol 
with NNRTI has been reported [36]. Consistent with previ-
ous reports, NRTI-only therapy was associated with lower 
rates of elevated total cholesterol [35, 37]. 
  We found a strong association between elevated total 
cholesterol level and higher CD4 cell counts, which was pre-
sent within each treatment category. Nevertheless, within 
each CD4 cell count stratum, the effect of antiretroviral ther-
apy was clearly observed, which indicates that the effect of 
antiretroviral substances certainly cannot solely be explained 
by a reversal to ‘normal’ pre-disease cholesterol levels as a 
result of improved cellular immunity. The level of HDL-
cholesterol, although to a lesser extent, likewise increased 
with more conserved cellular immunity, consistent with ob-
servations in the pre-HAART era [38]. For total cholesterol, 
the association with HIV-1 viral load was the inverse of the 
association with CD4 cell count. The latter has also been 
reported from other studies [39]. However, it could also be 
possible that these findings merely reflect the cumulative 
exposure to antiretrovirals. 
  In the VACH study, we have observed a high prevalence 
of other known and potential CVD risk factors among pa-
tients receiving either PI or NNRTI, including cigarette 
smoking, diabetes, hypertension and altered body composi-
tion. The overall prevalence of diabetes mellitus in the 
VACH study was 7.3%, similar to other studies that have 
shown an association between diabetes mellitus and use of 
PI [1, 27, 31], and recently with NRTI exposure [40]. A few 
studies have reported an increased prevalence of hyperten-
sion in PI-treated patients [3, 4] or in conjunction with 
lipodystrophy [41]. In our study, the associations between 
antiretroviral drug regimens and hypertension in univariable 
logistic models were no longer present after adjustment for 
other factors associated with hypertension. This is in odds 
with data from the DAD cohort showing no deleterious ef-
fect of any class of antiretrovirals on blood pressure [42]. 
There was a marked association between dyslipidemia and 
several of the other CVD risk factors on the one hand and 
clinical lipodystrophy on the other [43]. Current guidelines 
for the management of dyslipidemia in HIV-1-infected pa-
tients have been developed [44]. Assuming that dyslipidemia 
in HIV-1-infected will have similar long-term consequences 
to dyslipidemia in the general population, these guidelines 
also assume that the benefits of lipid lowering interventions 
will also extend to HIV-1-infected persons, and thus these 
are based on CVR stratification while the goals to be 
achieved are based on target values for LDL cholesterol and 
non-HDL cholesterol [43]. Despite that, we found that only 
between a fourth and a fifth of patients in our cohort needing 
LLT were effectively being treated, a figure somwwhat 
higher than those reported in previous years [34]. This find-
ing may have many causes, but among them the lack of LLT 
knowledge by HIV-1 treating physicians might be consid-
ered. In a recent report, it was shown that when dyslipidemic 
HIV-1-infected patients were addressed to a specialized lipid 
clinic, the percentage of those being treated with LLT sig-
nificantly increased [45]. 
  Recently, the issue of how young persons, with a low 
absolute risk may be at a substantially relative higher has 
been addressed in the European guidelines [46], and this is 
particularly the case for HIV-1-infected patients because 
even if its absolute risk is low, it may still be 10-12 times 
higher than that of a person with low risk factor, usually be-
cause the addition of cumulative risk factors. The present 
study shows that the use of potent antiretroviral therapy re-
sulting in more profound virus suppression and more pre-
served immunity, was associated with a high both relative 
and absolute risk of exhibiting risk factors for CHD. How 
these projections will translate to clinical events of CHD is 
difficult to predict, since it is assumed that there presumably 
will be a time lag from when factors known to accelerate the 
atherosclerotic process are induced and until clinical mani-
festations of atherosclerotic vascular disease occur. Present 
evidences suggest that HIV-1-infected patients have a 27% 
yearly risk of developing a cardiovascular event [47]. As 
many of these factors are likely to act synergistically, to-
gether with the underlying HIV-1 infection itself the time-lag 
cannot be reliably assessed. However, ongoing studies such 
as DAD [13] may provide fruitful comparisons between ex-
pected and observed CVD event rates [48]. Clearly, the man-
agement of CVR factors among our HIV-1-infected patients 
needs to be improved, and must follow two paths: a contin-
ued need for developing less harmful and better tolerated 
effective treatments for HIV-1 infection together with a bet-
ter knowledge of pharmaceutical and non-pharmaceutical 
measures directed at reducing CVD risk by HIV-1 physi-
cians. Given the high prevalence of smoking among our pa-
tients, strategies to quit smoking will likely prove cost-
effective in preventing CVD in HIV-1-infected patients. 
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APPENDIX: CUTT-OFF VALUES FOR SPECIFICA-
TION OF CVD RISK FACTORS IN HIV-1-INFECTED 
PATIENTS 
  The specification of risk factors is as follows. (i) Dyslipi-
demia: defined as elevated total cholesterol > 6.2 mmol/l 
(240 mg/dl), and/or decreased HDL-cholesterol < 0.9 mmol/l 
(35 mg/dl), and/or elevated triglycerides > 2.3 mmol/l (200 
mg/dl). [The cut-offs applied are based on cut-offs for high 
risk for CVD in the NCEP guidelines.] (ii) Older age: age > 
45 years for men and > 55 for women. (iii) Family history of 
coronary heart disease: first-degree relative with myocardial 
infarction before age 50. (iv) Previous CVD: patients’ own 
previous experience of myocardial infarction and/or stroke. 
(v) Hypertension: elevated systolic blood pressure > 140 
mmHg and/or elevated diastolic blood pressure > 90 mmHg, 
or usage of anti-hypertensive drugs. (vi) Diabetes: history of 
diabetes or usage of anti-diabetic therapy. (vii) Body mass 
index (BMI) was stratified in four categories: underweight 
(BMI < 18 kg/m
2), normal weight (BMI, 18–26 kg/m
2), 
overweight (BMI, 26.1–30 kg/m
2) and obesity (BMI,> 30 
kg/m
2). Obesity was considered a cardiovascular risk factor. 
(viii) Smoking: current cigarette smoking at inclusion in the 
study. (ix) Presence of clinical lipodystrophy was defined as 
either characteristic fat loss (from the face and/or extremi-
ties), central fat gain (abdominal and/or cervicodorsal) or 
mixed (at least one sign each of fat loss and central fat gain), 
as judged by the treating physician. 
  The specification of therapies to manage CVD risk fac-
tors were as follows: a) patients taking lipid-lowering agents 
b) anti-hypertensive medication c) anti-diabetic agents or 
insulin (derivatives) d) platelet aggregation inhibitors, and e) 
smoking cessation therapy. 
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